Innovative drug concept fluctuates and falls back, Asia-Pacific Pharmaceuticals hits limit down.

The concept of innovative drugs has seen a decline, with Asia-Pacific Pharmaceuticals hitting the limit down. Tianjin Pharmaceutical, Kangzhi Pharmaceutical, Shuanglu Pharmaceutical, Xinhua Pharmaceutical, Haichen Pharmaceutical, Junshi Biosciences, and Baihua Medicine are among the top decliners.